Relationship of the Degree of Sarcopenia with the Severity of Nonalcoholic Fatty Liver Disease and Cardiometabolic Risk in Adolescents

Overview

Journal Life (Basel)

Specialty Biology

Date 2024 Nov 27

PMID 39598255

Authors

Yoowon Kwon

Jin A Chung

You Jin Choi

Yoo Min Lee

So Yoon Choi

In Hyuk Yoo

Tae Hyeong Kim

Su Jin Jeong

Affiliations

Soon will be listed here.

Abstract

The association between nonalcoholic fatty liver disease (NAFLD) and sarcopenia has been suggested. We investigated sarcopenia's impact on NAFLD severity and its relationship with cardiometabolic risk in adolescents. We conducted a retrospective study on 122 patients aged 13-18 years and diagnosed with both NAFLD and sarcopenia by laboratory tests, abdominal ultrasound (US), and multifrequency bioelectrical impedance analysis. Sarcopenia was stratified into tertiles based on the skeletal muscle-to-fat ratio (MFR), NAFLD severity was established by the US, and cardiometabolic risk was assessed by the triglyceride-glucose (TyG) index and the atherogenic index of plasma (AIP). Compared with the other patients, those in the lower MFR tertiles exhibited a greater severity of NAFLD ( < 0.001) and significantly higher TyG index and AIP. The independent effect of MFR was observed to have a negative correlation with the severity of NAFLD ( < 0.001). Based on the aforementioned results, the degree of sarcopenia can be considered as one of the risk factors of severe NAFLD and might be an indicator of cardiometabolic risk in adolescents. Weight training to reach the amount of muscle mass could be included in the treatment strategies to improve or prevent NAFLD in adolescents with sarcopenia.

References

Zembura M, Matusik P . Sarcopenic Obesity in Children and Adolescents: A Systematic Review. Front Endocrinol (Lausanne). 2022; 13:914740. PMC: 9198401. DOI: 10.3389/fendo.2022.914740. View

Zhang Y, Fowler K, Hamilton G, Cui J, Sy E, Balanay M . Liver fat imaging-a clinical overview of ultrasound, CT, and MR imaging. Br J Radiol. 2018; 91(1089):20170959. PMC: 6223150. DOI: 10.1259/bjr.20170959. View

Simental-Mendia L, Rodriguez-Moran M, Guerrero-Romero F . The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008; 6(4):299-304. DOI: 10.1089/met.2008.0034. View

Beyer I, Mets T, Bautmans I . Chronic low-grade inflammation and age-related sarcopenia. Curr Opin Clin Nutr Metab Care. 2011; 15(1):12-22. DOI: 10.1097/MCO.0b013e32834dd297. View

Chakravarthy M, Siddiqui M, Forsgren M, Sanyal A . Harnessing Muscle-Liver Crosstalk to Treat Nonalcoholic Steatohepatitis. Front Endocrinol (Lausanne). 2021; 11:592373. PMC: 7786290. DOI: 10.3389/fendo.2020.592373. View

Lee Y, Jung K, Kim S, Yoon H, Yun Y, Lee B . Sarcopaenia is associated with NAFLD independently of obesity and insulin resistance: Nationwide surveys (KNHANES 2008-2011). J Hepatol. 2015; 63(2):486-93. DOI: 10.1016/j.jhep.2015.02.051. View

Beaudart C, Biver E, Reginster J, Rizzoli R, Rolland Y, Bautmans I . Validation of the SarQoL®, a specific health-related quality of life questionnaire for Sarcopenia. J Cachexia Sarcopenia Muscle. 2016; 8(2):238-244. PMC: 5377391. DOI: 10.1002/jcsm.12149. View

Zambon Azevedo V, Silaghi C, Maurel T, Silaghi H, Ratziu V, Pais R . Impact of Sarcopenia on the Severity of the Liver Damage in Patients With Non-alcoholic Fatty Liver Disease. Front Nutr. 2022; 8:774030. PMC: 8802760. DOI: 10.3389/fnut.2021.774030. View

Spiezia C, Di Rosa C, Fintini D, Ferrara P, De Gara L, Khazrai Y . Nutritional Approaches in Children with Overweight or Obesity and Hepatic Steatosis. Nutrients. 2023; 15(11). PMC: 10255273. DOI: 10.3390/nu15112435. View

10.

Hwa Ooi P, Thompson-Hodgetts S, Pritchard-Wiart L, Gilmour S, Mager D . Pediatric Sarcopenia: A Paradigm in the Overall Definition of Malnutrition in Children?. JPEN J Parenter Enteral Nutr. 2019; 44(3):407-418. DOI: 10.1002/jpen.1681. View

11.

Kwon Y, Jeong S . Relative Skeletal Muscle Mass Is an Important Factor in Non-Alcoholic Fatty Liver Disease in Non-Obese Children and Adolescents. J Clin Med. 2020; 9(10). PMC: 7588960. DOI: 10.3390/jcm9103355. View

12.

Song K, Park G, Lee H, Choi Y, Oh J, Choi H . Prediction of Insulin Resistance by Modified Triglyceride Glucose Indices in Youth. Life (Basel). 2021; 11(4). PMC: 8066260. DOI: 10.3390/life11040286. View

13.

Anderson E, Howe L, Jones H, Higgins J, Lawlor D, Fraser A . The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10(10):e0140908. PMC: 4626023. DOI: 10.1371/journal.pone.0140908. View

14.

Saadeh S, Younossi Z, Remer E, Gramlich T, Ong J, Hurley M . The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology. 2002; 123(3):745-50. DOI: 10.1053/gast.2002.35354. View

15.

Cook S, Weitzman M, Auinger P, Nguyen M, Dietz W . Prevalence of a metabolic syndrome phenotype in adolescents: findings from the third National Health and Nutrition Examination Survey, 1988-1994. Arch Pediatr Adolesc Med. 2003; 157(8):821-7. DOI: 10.1001/archpedi.157.8.821. View

16.

Prado C, Wells J, Smith S, Stephan B, Siervo M . Sarcopenic obesity: A Critical appraisal of the current evidence. Clin Nutr. 2012; 31(5):583-601. DOI: 10.1016/j.clnu.2012.06.010. View

17.

Yoon J, Shim Y, Lee H, Hwang I, Hwang J . A population-based study of TyG index distribution and its relationship to cardiometabolic risk factors in children and adolescents. Sci Rep. 2021; 11(1):23660. PMC: 8654923. DOI: 10.1038/s41598-021-03138-6. View

18.

Lioy B, Webb R, Amirabdollahian F . The Association between the Atherogenic Index of Plasma and Cardiometabolic Risk Factors: A Review. Healthcare (Basel). 2023; 11(7). PMC: 10094587. DOI: 10.3390/healthcare11070966. View

19.

Neuschwander-Tetri B . Non-alcoholic fatty liver disease. BMC Med. 2017; 15(1):45. PMC: 5330146. DOI: 10.1186/s12916-017-0806-8. View

20.

Malmstrom T, Miller D, Simonsick E, Ferrucci L, Morley J . SARC-F: a symptom score to predict persons with sarcopenia at risk for poor functional outcomes. J Cachexia Sarcopenia Muscle. 2016; 7(1):28-36. PMC: 4799853. DOI: 10.1002/jcsm.12048. View